Skip to main content
SpringerLink
Log in

Diagnosis and treatment of parkinson’s disease in the elderly

  • Clinical Review
  • Published:
Journal of General Internal Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1988;51:745–52.

    PubMed  CAS  Google Scholar 

  2. Marttila RJ, Rinne UK. Epidemiology of Parkinson’s disease—an overview. J Neural Transm Gen Sect. 1981;51:135–48.

    Article  CAS  Google Scholar 

  3. Marttila RJ, Rinne UK. Temporal changes in the prevalence of Parkinson’s disease. Acta Neurol Scand. 1990;H82(suppl 128):28.

    Google Scholar 

  4. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism: a prospective study. Can J Neurol Sci. 1991;18:275–8.

    PubMed  CAS  Google Scholar 

  5. Hughes AJ, Daniel SE, Kilford L, Lees AJ. The accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181–4.

    PubMed  CAS  Google Scholar 

  6. Sage JI, Duvoisin RC. The Parkinson plus syndromes. In: Fahn S, Jankovic J (eds). Current Opinion in Neurology and Neurosurgery. Vol. 2. London: Gower Academic Journals, 1989;314–8.

    Google Scholar 

  7. Nieforth KA, Golbe LI. Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin Neuropharmacol. 1993;16:388–46.

    Article  Google Scholar 

  8. Quinn N. Multiple system atrophy—the nature of the beast. J Neurol Neurosurg Psychiatry. 1989;52(special suppl):78–89.

    Google Scholar 

  9. Hughes AJ, Colosimo C, Kleedorfer B, Daniel SE, Lees AJ. The dopaminergic response in multiple system atrophy. J Neurol Neurosurg Psychiatry. 1992;55:1009–13.

    PubMed  CAS  Google Scholar 

  10. Goetz CG, Tanner CM, Klawans HL. The pharmacology of olivopontocerebellar atrophy. Adv Neurol. 1984;41:143–8. Koller WC (eds). Parkinsonian syndromes. New York: Marcel

    PubMed  CAS  Google Scholar 

  11. Riley DE, Lang AE. Cortical-basal ganglionic degeneration. In: Stern MB, Koller WC (eds). Parkinsonian syndromes. New York: Marcel Dekker, 1993;379–92.

    Google Scholar 

  12. Findley LJ. Tremors: differential diagnosis and pharmacology. In: Jankovic J, Tolosa E (eds). Parkinson’s disease and movement disorders, 2nd ed. Baltimore: Williams & Wilkins, 1993;293–313.

    Google Scholar 

  13. Larsen TA, Caine DB. Essential tremor. Clin Neuropharmacol. 1983;6:185–206.

    Article  PubMed  CAS  Google Scholar 

  14. Ward CD, Duvoisin RC, Ince SE, Nutt JG, Eldridge R, Calne DB. Parkinson’s disease in 65 pairs of twins and in a set of quadruplets. Neurology. 1983;33:815–24.

    PubMed  CAS  Google Scholar 

  15. Lazzarini AM, Myers RH, Zimmerman TR Jr, et al. A clinical genetic study of Parkinson’s disease: evidence for dominant transmission. Neurology. 1994;44:499–506.

    PubMed  CAS  Google Scholar 

  16. Critchley M. Arteriosclerotic parkinsonism. Brain. 1929;52:23–83.

    Article  Google Scholar 

  17. Thompson PD, Marsden CD. Gait disorder of subcortical arteriosclerotic encephalopathy: Binswanger’s disease. Mov Disord. 1987;2:1–8.

    Article  PubMed  CAS  Google Scholar 

  18. Bennett DA, Wilson RS, Gilley DW, Fox JH. Clinical diagnosis of Binswanger’s disease. J Neurol Neurosurg Psychiatry. 1990;53:961–5.

    PubMed  CAS  Google Scholar 

  19. Snider SR, Fahn S, Isgreen WP, Cote LJ. Primary sensory symptoms in parkinsonism. Neurology. 1976;26:423–9.

    PubMed  CAS  Google Scholar 

  20. Goetz CG, Tanner CM, Levy M, Wilson RS, Garron DG. Pain in idiopathic Parkinson’s disease [abstract]. Neurology. 1985;35(suppl 1):200.

    Google Scholar 

  21. Quinn NP, Koller WC, Lang AE, Marsden CD. Painful Parkinson’s disease. Lancet. 1986;1:1366–9.

    Article  PubMed  CAS  Google Scholar 

  22. LeWitt PA, Burns RS, Newman RP. Dystonia in untreated parkinsonism. Clin Neuropharmacol. 1986;9:293–7.

    Article  PubMed  CAS  Google Scholar 

  23. Katchen M, Duvoisin RC. Parkinsonism following dystonia in three patients. Mov Disord. 1986;1:151–7.

    Article  PubMed  CAS  Google Scholar 

  24. Mayeux R, Stern Y, Rosenstein R, et al. An estimate of the prevalence of dementia in idiopathic Parkinson’s disease. Arch Neurol. 1988;45:260–2.

    PubMed  CAS  Google Scholar 

  25. Mayeux R, Chen J, Mirabello E, et al. An estimate of the incidence of dementia in idiopathic Parkinson’s disease. Neurology. 1990;40:1513–7.

    PubMed  CAS  Google Scholar 

  26. Mayeux R, Denaro J, Hemenegildo N, et al. A population-based investigation of Parkinson’s disease with and without dementia. Relationship to age and gender. Arch Neurol. 1992;49:492–7.

    PubMed  CAS  Google Scholar 

  27. Sage JI, Mark MH. Diffuse Lewy body disease. In: Stern MB, Koller WC (eds). Parkinsonian syndromes. New York: Marcel Dekker, 1993;393–411.

    Google Scholar 

  28. Mark MH, Dickson DW. The spectrum of Lewy body disease [abstract]. Ann Clin Lab Sci. 1992;22:270.

    Google Scholar 

  29. Davis KL, Thal LJ, Gamzu ER, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer’s disease. The Tacrine Collaborative Study Group. N Engl J Med. 1992;327:1253–9.

    Article  PubMed  CAS  Google Scholar 

  30. Friedman JH. Drug-induced parkinsonism. In: Lang AE, Weiner WJ (eds). Drug-induced movement disorders. Mount Kisco, NY: Futura Publishing, 1992;41–83.

    Google Scholar 

  31. Lang AE. Miscellaneous drug-induced movement disorders. In: Lang AE, Weiner WJ (eds). Drug-induced movement disorders. Mount Kisco, NY: Futura Publishing, 1992;399–81.

    Google Scholar 

  32. Micheli F, Fernandez Pardal M, Gatto M, et al. Flunarizine-and cinnarizine-induced extrapyramidal reactions. Neurology. 1987;37:881–4.

    PubMed  CAS  Google Scholar 

  33. Gimenez-Roldan S, Mateo D. Cinnarizine-induced parkinsonism: susceptibility related to aging and essential tremor. Clin Neuropharmacol. 1991;14:156–64.

    Article  PubMed  CAS  Google Scholar 

  34. Moretti A, Lucantoni C. Flunarizine-induced parkinsonism: clinical report. Ital J Neurol Sci. 1988;9:295–7.

    Article  PubMed  CAS  Google Scholar 

  35. Dick RS, Barold SS. Diltiazem-induced parkinsonism. Am J Med. 1989;87:95–6.

    Article  PubMed  CAS  Google Scholar 

  36. Garcia-Albea E, Jimenez-Jimenez FJ, Ayuso-Peralta L, Cabrera-Valdivia F, Vaquero A, Tejeiro J. Parkinsonism unmasked by verapamil. Clin Neuropharmacol. 1993;16:263–5.

    Article  PubMed  CAS  Google Scholar 

  37. Micheli FE, Fernandez Pardal MM, Giannaula R, et al. Movement disorders and depression due to flunarizine and cinnarizine. Mov Disord. 1989;4:139–46.

    Article  PubMed  CAS  Google Scholar 

  38. Fernandez Pardal MM, Fernandez Pardal J, Micheli F. Effect of flunarizine and nifedipine on the3H dopamine release by potassium in the rat caudate nucleus. Acta Physiol Pharmacol Ther Latinoam. 1987;37:156–8.

    Google Scholar 

  39. Fernandez Pardal MM, Fernandez Pardal J, Micheli F. Aggravation of Parkinson’s disease by cinnarizine. J Neurol Neurosurg Psychiatry. 1988;51:158–9.

    PubMed  CAS  Google Scholar 

  40. Sandyk R. Parkinsonism induced by captopril. Clin Neuropharmacol. 1985;8:197–200.

    Article  PubMed  CAS  Google Scholar 

  41. Groden BM. Parkinsonism occurring with methyldopa treatment. Br Med J. 1963;1:1001.

    PubMed  CAS  Google Scholar 

  42. Peaston MJT. Parkinsonism associated with alphamethyldopa therapy. Br Med J. 1963;2:168.

    Google Scholar 

  43. Strang RR. Parkinsonism occurring during methyldopa therapy. Can Med Assoc J. 1966;95:928–9.

    PubMed  CAS  Google Scholar 

  44. Boranic M, Raci F. A Parkinson-like syndrome as side effect of chemotherapy with vincristine and adriamycin in a child with acute leukemia. Biomedicine. 1979;31:124–5.

    PubMed  CAS  Google Scholar 

  45. Armon C, Miller P, Carwile S, et al. Valproate-induced parkinsonism-dementia syndrome: clinical features [abstract]. Mov Disord. 1991;6:269.

    Article  Google Scholar 

  46. Lang AE. Lithium and parkinsonism. Ann Neurol. 1984;15:214.

    Article  PubMed  CAS  Google Scholar 

  47. Reches A, Teitler J, Lavy S. Parkinsonism due to lithium carbonate poisoning. Arch Neurol. 1981;38:471.

    PubMed  CAS  Google Scholar 

  48. Prensky AL, DeVivo DC, Palkes H. Severe bradykinesia as a manifestation of toxicity to anti-epileptic medications. J Pediatr. 1974;78:700–4.

    Google Scholar 

  49. Luque AF, Selhorst JB, Petruska P. Parkinsonism induced by high dose cytosine arabinoside. Mov Disord. 1987;2:219–22.

    Article  PubMed  CAS  Google Scholar 

  50. Carlen PI, Lee MA, Jacob MA, Livshits O. Parkinsonism provoked by alcoholism. Ann Neurol. 1981;9:84–6.

    Article  PubMed  CAS  Google Scholar 

  51. Lang AE, Marsden CD, Obeso JA, Parkes JD. Alcohol and Parkinson’s disease. Ann Neurol. 1982;12:254–6.

    Article  PubMed  CAS  Google Scholar 

  52. Shen WW. Extrapyramidal symptoms associated with alcohol withdrawal. Biol Psychiatry. 1984;19:1037–43.

    PubMed  CAS  Google Scholar 

  53. Nieman J, Borg S, Wahlund L-O. Parkinsonism and dyskinesia during ethanol withdrawal. Br J Addict. 1988;83:437–9.

    Article  Google Scholar 

  54. Hachinski V. Timing of levodopa therapy. Arch Neurol. 1986;43:407.

    PubMed  CAS  Google Scholar 

  55. Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson’s disease. Lancet. 1977;1:345–9.

    Article  PubMed  CAS  Google Scholar 

  56. Markham CH, Diamond SG. Evidence to support early levodopa therapy in Parkinson’s disease. Neurology. 1981;31:125–31.

    PubMed  CAS  Google Scholar 

  57. Olanow CW. Oxidation reactions in Parkinson’s disease. Neurology. 1990;40(suppl 3):32–7.

    PubMed  Google Scholar 

  58. Sage JI, Mark MH. The rationale for continuous dopaminergic stimulation in patients with advanced Parkinson’s disease. Neurology. 1992;42(suppl 1):23–8.

    PubMed  CAS  Google Scholar 

  59. Sage JI, Duvoisin RC. The modern managment of Parkinson’s disease. In: Chokroverty S (ed). Movement Disorders. Costa Mesa, CA: PMA Publishing. 1990;179–200.

    Google Scholar 

  60. Duvoisin RC, Sage JI. The spectrum of Parkinson’s disease. In: Chokroverty S (ed). Movement Disorders. Costa Mesa, CA: PMA Publishing. 1990;159–77.

    Google Scholar 

  61. Mayeux R, Williams JBW, Stern Y, Côté I. Depression and Parkinson’s disease. Adv Neurol. 1984;40:451–61.

    Google Scholar 

  62. Menza M, Sage J, Marshall E, Cody R, Duvoisin R. Mood changes and “on-off” phenomena in Parkinson’s disease. Mov Disord. 1990;5:148–51.

    Article  PubMed  CAS  Google Scholar 

  63. Yeh KC, August TF, Bush DF, et al. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology. 1989;39(suppl 2):25–38.

    PubMed  CAS  Google Scholar 

  64. Evans MA, Broe GA, Triggs EJ, Cheung M, Creasy H, Paull PD. Gastric emptying rate and the systemic availability of levodopa in the elderly parkinsonian patient. Neurology. 1981;31:1288–94.

    PubMed  CAS  Google Scholar 

  65. Parkes JD, Debono AG, Marsden CD. Bromocriptine in parkinsonism: long term treatment, dose response and comparison with levodopa. J Neurol Neurosurg Psychiatry. 1976;39:1101–8.

    Article  PubMed  CAS  Google Scholar 

  66. Sage JI, Duvoisin RC. Long-term efficacy of pergolide in patients with Parkinson’s disease. Clin Neuropharmacol. 1986;9:160–4.

    Article  PubMed  CAS  Google Scholar 

  67. Sage JI, Duvoisin RC. Pergolide therapy in Parkinson’s disease: a double-blind, placebo-controlled study. Clin Neuropharmacol. 1985;8:260–5.

    Article  PubMed  CAS  Google Scholar 

  68. Sage JI, Mark MH. Comparison of controlled-release Sinemet (CR-4) and standard Sinemet (25/100) in advanced Parkinson’s disease: a double-blind, crossover study. Clin Neuropharmacol. 1988;11:174–9.

    Article  PubMed  CAS  Google Scholar 

  69. Mark MH, Sage JI. Long-term efficacy of controlled-release carbiodopa/levodopa in patients with advanced Parkinson’s disease. Ann Clin Lab Sci. 1989;19:415–21.

    PubMed  CAS  Google Scholar 

  70. Mark MH, Sage JI. Controlled-release carbidopa/levodopa (Sinemet) in combination with standard Sinemet therapy in advanced Parkinson’s disease. Ann Clin Lab Sci. 1989;19:101–6.

    PubMed  CAS  Google Scholar 

  71. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science. 1989;245:519–22.

    Article  PubMed  CAS  Google Scholar 

  72. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med. 1989;321:1364–71.

    Article  Google Scholar 

  73. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med. 1993;328:176–83.

    Article  Google Scholar 

  74. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson’s disease. Neurology. 1993;43:2227–9.

    PubMed  CAS  Google Scholar 

  75. McHale DM, Sage JI. Hallucinations and confusion following pergolide withdrawal. Clin Neuropharmacol. 1988;11:545–8.

    Article  PubMed  CAS  Google Scholar 

  76. Friedman JH, Lannon MC. Clozapine in the treatment of psychosis in Parkinson’s disease. Neurology. 1989;39:1219–21.

    PubMed  CAS  Google Scholar 

  77. Jarvie KR, Caron MG. Heterogeneity of dopamine receptors. Adv Neurol. 1993;60:325–33.

    PubMed  CAS  Google Scholar 

  78. Synder AM, Stricker EM, Zigmond MJ. Stress-induced neurological impairments in an animal model of parkinsonism. Ann Neurol. 1985;18:544–51.

    Article  Google Scholar 

  79. Goetz CG, Stebbins GT. Effects of head trauma from motor vehicle accidents on Parkinson’s disease. Ann Neurol. 1991;29:191–3.

    Article  PubMed  CAS  Google Scholar 

  80. Sage JI, Trooskin S, Sonsalla PK, Heikkila RE. Experience with continuous, enteral, levodopa infusions in the treatment of nine patients with advanced Parkinson’s disease. Neurology. 1989;39(suppl 2):60–3.

    PubMed  CAS  Google Scholar 

  81. Dietz MA, Goetz CG, Stebbins GT. Evaluation of a modified inverted walking stick as a treatment for parkinsonian freezing episodes. Mov Disord. 1990;5:243–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Robert Wood Johnson Medical School, CN-19, 08903, New Brunswick, NJ

    Jacob I. Sage MD

Authors
  1. Jacob I. Sage MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Margery H. Mark MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Received from the Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, New Jersey.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sage, J.I., Mark, M.H. Diagnosis and treatment of parkinson’s disease in the elderly. J Gen Intern Med 9, 583–589 (1994). https://doi.org/10.1007/BF02599289

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02599289

Keywords

Search

Navigation